Turner Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

Turner Investments’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-6,760	Closed	-$458K	–	259
2016 Q3	$458K	Sell	6,760 -3,610	-35%	-$255K	0.15%	146
2016 Q2	$575K	Buy	+10,370	New	+$653K	0.18%	131
2014 Q2	–	Sell	-35,670	Closed	-$2.39M	–	549
2014 Q1	$2.39M	Buy	+35,670	New	+$2.76M	0.06%	300

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Turner Investments's ALNY Position: Q4 2016 in Review

Turner Investments sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2016, closing a stake of 6,760 shares — an estimated $458K sold.

Turner Investments first reported a position in ALNY in Q1 2014 and held it in 3 quarters. The position peaked at $2.39M in Q1 2014. 211 funds tracked by Wall St. Rank hold ALNY as of Q4 2016.

Turner Investments reported no remaining Alnylam Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Turner Investments sold 6,760 Alnylam Pharmaceuticals shares in Q4 2016, an estimated $458K.
Turner Investments first reported a position in Alnylam Pharmaceuticals in Q1 2014 and held it in 3 quarters.
Turner Investments's Alnylam Pharmaceuticals position peaked at $2.39M in Q1 2014.
211 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2016.

Based on Turner Investments's 13F filing for Q4 2016, filed 8 Feb 2017.